Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
Home
Next Post
Previous Post
test
September 30, 2023
/
Uncategorized
1
Like
Share
the Post
About
the Author
Related
Posts
Phase I results from a phase 1/2 multi-center study of
nab
-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Read More
David Dornan, PhD
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
in a Phase 2, Multicenter, Open-label Tumor-Agnostic Trial: PRECISION 1
Baiteng Zhao, PhD
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
and
TSC2
(PRECISION 1)
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Patients With Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of
nab
-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
and
TSC2
Read More
Neil Desai, PhD
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.